Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpedsurg.2022.06.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenetic guided drug therapy - how to deal with phenoconversion in polypharmacy.
Expert Opin Drug Metab Toxicol
January 2025
Institute of Psychology, University of Innsbruck, Innsbruck, Austria.
Introduction: The prevalence of polypharmacy and the increasing availability of pharmacogenetic information in clinical practice have raised the prospect of data-driven clinical decision-making when addressing the issues of drug-drug interactions and genetic polymorphisms in metabolizing enzymes. Inhibition of metabolizing enzymes in drug interactions can lead to genotype-phenotype discrepancies (phenoconversion) that reduce the relevance of individual pharmacogenetic information.
Areas Covered: The aim of this review is to provide an overview of existing models of phenoconversion, and we discuss how phenoconversion models may be developed to estimate joint drug-interactions and genetic effects.
Blue light-activated 5,10,15,20-tetrakis(4-bromophenyl)porphyrin for photodynamic eradication of drug-resistant .
RSC Adv
December 2024
Laboratory of Chemical Biology, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun Jilin 130022 China
Article Synopsis
- Photodynamic therapy (PDT), particularly blue light-mediated PDT (BL-PDT), is effective against drug-resistant bacterial infections, especially for treating skin infections due to its targeted absorption and minimal damage to deeper tissues.
- Newly developed porphyrin derivatives are being explored as photosensitizers for BL-PDT, with five different compounds investigated for their effectiveness against methicillin-resistant Staphylococcus aureus (MRSA).
- Among these, TBPP shows excellent antibacterial properties by generating reactive oxygen species, disrupting cell membranes, and significantly enhancing wound healing in infected skin models.
Osimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.
Pril (Makedon Akad Nauk Umet Odd Med Nauki)
November 2024
Faculty of Medicine, University Clinic of Radiotherapy and Oncology, Skopje, Macedonia.
Purpose: To investigate the rare side effects of Osimertinib in a case of toxic epidermal necrosis.
Case Presentation: We report on a case of a 44-year old woman with lung adenocarcinoma harboring an EGFR-sensitizing mutation who was treated with Osimertinib as the second-line treatment. Ten days after Osimertinib initiation, a diffuse erythematous rash rapidly spread over the patient's trunk along with vesicles and purpuric macules; furthermore, she developed erythema and exfoliation on the face and trunk and severe mucositis.
Development of a Novel Mixed-Metal-Organic Framework: An Innovative Photocatalyst for Simultaneous Cr(VI) Reduction and Phenol Degradation.
Inorg Chem
December 2024
The Organic Chemistry Research Laboratory (OCRL), Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan 45371-38791, Iran.
Article Synopsis
- * The research focuses on a specific type of photocatalyst called mixed-metal organic frameworks (MM-MOFs), particularly a newly synthesized structure named FeCoMOF, which incorporates iron and cobalt for enhanced performance.
- * Experiments were carried out to test the FeCoMOF's effectiveness in reducing chromium (Cr(VI)) and degrading phenol, analyzing factors like substrate concentration and pH to understand the photocatalytic processes involved.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!